The Effect of Mycophenolate Mofetil on Disease Development in the gld.apoE-/- Mouse Model of Accelerated Atherosclerosis and Systemic Lupus Erythematosus

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Richez, Christophe ^a,b,c   Richards, Rocco J ^c   Duffau, Pierre ^b,d   Weitzner, Zachary ^c   Andry, Christopher D ^c   Rifkin, Ian R ^c   Aprahamian, Tamar ^c  

^a HÔPITAL PELLEGRIN   (France)

^b CNRS Bordeaux Segalen University   (France)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HÔPITAL SAINT ANDRÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL DIET; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG MECHANISM; GENE; GLD.APOE GENE; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHADENOPATHY; MOUSE; MOUSE STRAIN; NONHUMAN; PHENOTYPE; SPLENOMEGALY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; AUTOANTIBODIES; BODY WEIGHT; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; EATING; FAS LIGAND PROTEIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHATIC DISEASES; MICE; MYCOPHENOLIC ACID; NEPHRITIS; SPLENOMEGALY;

MURINAE; MUS;

EID: 84876012717     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061042     Document Type: Article

References (31)

1. Tsokos GC, (2011) Systemic lupus erythematosus. N Engl J Med 365: 2110-2121.
2. Pons-Estel GJ, Alarcon GS, Scofield L, Reinlib L, Cooper GS, (2010) Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum 39: 257-268.
3. Westerweel PE, Luyten RK, Koomans HA, Derksen RH, Verhaar MC, (2007) Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus. Arthritis Rheum 56: 1384-1396.
4. Urowitz MB, Gladman D, Ibanez D, Bae SC, Sanchez-Guerrero J, et al. (2010) Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus. Arthritis Care Res (Hoboken) 62: 881-887.
5. Galkina E, Ley K, (2009) Immune and inflammatory mechanisms of atherosclerosis. Annu Rev Immunol 27: 165-197.
6. Ross R, (1999) Atherosclerosis-an inflammatory disease. N Engl J Med 340: 115-126.
7. Jung H, Bobba R, Su J, Shariati-Sarabi Z, Gladman DD, et al. (2010) The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum 62: 863-868.
8. Ferreira GA, Navarro TP, Telles RW, Andrade LE, Sato EI, (2007) Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. Rheumatology (Oxford) 46: 1560-1565.
9. Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, et al. (2011) Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 365: 1886-1895.
10. Allison AC, Eugui EM, (1993) Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol Rev 136: 5-28.
11. Franklin TJ, Cook JM, (1969) The inhibition of nucleic acid synthesis by mycophenolic acid. Biochem J 113: 515-524.
12. Gibson WT, Hayden MR, (2007) Mycophenolate mofetil and atherosclerosis: results of animal and human studies. Ann N Y Acad Sci 1110: 209-221.
13. van Leuven SI, van Wijk DF, Volger OL, de Vries JP, van der Loos CM, et al. (2010) Mycophenolate mofetil attenuates plaque inflammation in patients with symptomatic carotid artery stenosis. Atherosclerosis 211: 231-236.
14. Aprahamian T, Rifkin I, Bonegio R, Hugel B, Freyssinet JM, et al. (2004) Impaired clearance of apoptotic cells promotes synergy between atherogenesis and autoimmune disease. J Exp Med 199: 1121-1131.
15. Ng R (2004) Drugs development and preclinical studies. In: Sons JW, editor. Drugs: From Discovery to Approval. 107-138.
16. Sedgwick C, Pokras MA, (1988) Extrapolating rational drug doses and treatment periods by allometric scaling. Proceedings of the 55th Annual Meeting of the American Animal Hospital Association. Washington, D. C: 156-157.
17. Komori H, Furukawa H, Mori S, Ito MR, Terada M, et al. (2006) A signal adaptor SLAM-associated protein regulates spontaneous autoimmunity and Fas-dependent lymphoproliferation in MRL-Faslpr lupus mice. J Immunol 176: 395-400.
18. Epinette WW, Parker CM, Jones EL, Greist MC, (1987) Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficacy, and safety. J Am Acad Dermatol 17: 962-971.
19. Van Bruggen MC, Walgreen B, Rijke TP, Berden JH, (1998) Attenuation of murine lupus nephritis by mycophenolate mofetil. J Am Soc Nephrol 9: 1407-1415.
20. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, et al. (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20: 1103-1112.
21. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, et al. (2000) Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 343: 1156-1162.
22. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, et al. (2005) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353: 2219-2228.
23. Ong LM, Hooi LS, Lim TO, Goh BL, Ahmad G, et al. (2005) Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology (Carlton) 10: 504-510.
24. Kelley VE, Roths JB, (1985) Interaction of mutant lpr gene with background strain influences renal disease. Clin Immunol Immunopathol 37: 220-229.
25. Lockshin MD, Salmon JE, Roman MJ, (2001) Atherosclerosis and lupus: a work in progress. Arthritis Rheum 44: 2215-2217.
26. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, et al. (1997) Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 145: 408-415.
27. Riboldi P, Gerosa M, Luzzana C, Catelli L, (2002) Cardiac involvement in systemic autoimmune diseases. Clin Rev Allergy Immunol 23: 247-261.
28. van Leuven SI, Kastelein JJ, Allison AC, Hayden MR, Stroes ES, (2006) Mycophenolate mofetil (MMF): firing at the atherosclerotic plaque from different angles? Cardiovasc Res 69: 341-347.
29. Huang HD, Liu ZH, Zhu XJ, Chen ZH, Li LS, (2002) Inhibition of mycophenolic acid on NF-kappaB activity in human endothelial cells. Acta Pharmacol Sin 23: 649-653.
30. Raisanen-Sokolowski A, Vuoristo P, Myllarniemi M, Yilmaz S, Kallio E, et al. (1995) Mycophenolate mofetil (MMF, RS-61443) inhibits inflammation and smooth muscle cell proliferation in rat aortic allografts. Transpl Immunol 3: 342-351.
31. van Leuven SI, Mendez-Fernandez YV, Wilhelm AJ, Wade NS, Gabriel CL, et al. (2012) Mycophenolate mofetil but not atorvastatin attenuates atherosclerosis in lupus-prone LDLr(-/-) mice. Ann Rheum Dis 71: 408-414.